|
|
Blood, 1 October 2006, Vol. 108, No. 7, pp. 2244-2247.
Prepublished online as a Blood First Edition Paper on June 13, 2006; DOI 10.1182/blood-2006-04-013052.
Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Jean-Sébastien Hulot,
Alessandra Bura,
Eric Villard,
Michel Azizi,
Véronique Remones,
Catherine Goyenvalle,
Martine Aiach,
Philippe Lechat, and
Pascale Gaussem
From the Assistance PubliqueHôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Service de Pharmacologie, Unité de Pharmacogénétique, Université Pierre et Marie Curie-Paris 6, Unite Mixte de Recherche (UMR) S 621, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France; AP-HP, Hôpital Européen Georges Pompidou, Service d'Hématologie Biologique, INSERM Unité 765, Université Paris-Descartes, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Centre d'Investigations Biomédicales, Paris, France; and AP-HP, Hôpital Européen Georges Pompidou, Centre d'Investigations Cliniques, INSERM, CIC 9201, Université Paris-Descartes, Paris, France.
The capacity of clopidogrel to inhibit ADP-induced platelet aggregation shows wide intersubject variability. To determine whether frequent functional variants of genes coding for candidate cytochrome P450 (CYP) isoenzymes involved in clopidogrel metabolic activation (CYP2C19*2, CYP2B6*5, CYP1A2*1F, and CYP3A5*3 variants) influence the platelet responsiveness to clopidogrel, we conducted a prospective pharmacogenetic study in 28 healthy white male volunteers treated for 7 days with clopidogrel 75 mg/d. We observed that pharmacodynamic response to clopidogrel was significantly associated with the CYP2C19 genotype. Twenty of the subjects were wild-type CYP2C19 (*1/*1) homozygotes, while the other 8 subjects were heterozygous for the loss-of-function polymorphism CYP2C19*2 (*1/*2). Baseline platelet activity was not influenced by the CYP2C19 genotype. In contrast, platelet aggregation in the presence of 10 µM ADP decreased gradually during treatment with clopidogrel 75 mg once daily in *1/*1 subjects, reaching 48.9% ± 14.9% on day 7 (P < .001 vs baseline), whereas it did not change in *1/*2 subjects (71.8% ± 14.6% on day 7, P = .22 vs baseline, and P < .003 vs *1/*1 subjects). Similar results were found with VASP phosphorylation. The CYP2C19*2 loss-of-function allele is associated with a marked decrease in platelet responsiveness to clopidogrel in young healthy male volunteers and may therefore be an important genetic contributor to clopidogrel resistance in the clinical setting.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. Hagihara, M. Kazui, A. Kurihara, M. Yoshiike, K. Honda, O. Okazaki, N. A. Farid, and T. Ikeda
A Possible Mechanism for the Differences in Efficiency and Variability of Active Metabolite Formation from Thienopyridine Antiplatelet Agents, Prasugrel and Clopidogrel
Drug Metab. Dispos.,
November 1, 2009;
37(11):
2145 - 2152.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Cuisset, C. Frere, J. Quilici, R. Poyet, B. Gaborit, L. Bali, O. Brissy, P.-E. Morange, M.-C. Alessi, and J.-L. Bonnet
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.
J. Am. Coll. Cardiol.,
September 22, 2009;
54(13):
1149 - 1153.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Marin, R. Gonzalez-Conejero, P. Capranzano, T. A. Bass, V. Roldan, and D. J. Angiolillo
Pharmacogenetics in cardiovascular antithrombotic therapy.
J. Am. Coll. Cardiol.,
September 15, 2009;
54(12):
1041 - 1057.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. R. Shuldiner, J. R. O'Connell, K. P. Bliden, A. Gandhi, K. Ryan, R. B. Horenstein, C. M. Damcott, R. Pakyz, U. S. Tantry, Q. Gibson, et al.
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
JAMA,
August 26, 2009;
302(8):
849 - 857.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Wallentin
P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
Eur. Heart J.,
August 2, 2009;
30(16):
1964 - 1977.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Verstuyft, T. Simon, and R. B. Kim
Personalized medicine and antiplatelet therapy: ready for prime time?
Eur. Heart J.,
August 2, 2009;
30(16):
1943 - 1963.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Varenhorst, S. James, D. Erlinge, J. T. Brandt, O. O. Braun, M. Man, A. Siegbahn, J. Walker, L. Wallentin, K. J. Winters, et al.
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
Eur. Heart J.,
July 2, 2009;
30(14):
1744 - 1752.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. B Norgard, K. D Mathews, and G. C Wall
Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors
Ann. Pharmacother.,
July 1, 2009;
43(7):
1266 - 1274.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Pena, J.-P. Collet, J.-S. Hulot, J. Silvain, O. Barthelemy, F. Beygui, C. Funck-Brentano, and G. Montalescot
Can We Override Clopidogrel Resistance?
Circulation,
June 2, 2009;
119(21):
2854 - 2857.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Mega, S. L. Close, S. D. Wiviott, L. Shen, R. D. Hockett, J. T. Brandt, J. R. Walker, E. M. Antman, W. L. Macias, E. Braunwald, et al.
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
Circulation,
May 19, 2009;
119(19):
2553 - 2560.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. F. Ford
Clopidogrel Resistance: Pharmacokinetic or Pharmacogenetic?
J. Clin. Pharmacol.,
May 1, 2009;
49(5):
506 - 512.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Roden and C. M. Stein
Clopidogrel and the Concept of High-Risk Pharmacokinetics
Circulation,
April 28, 2009;
119(16):
2127 - 2130.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, K. Dorrler, T. Morath, A. Schomig, A. Kastrati, and N. von Beckerath
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
Eur. Heart J.,
April 2, 2009;
30(8):
916 - 922.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Desta, A. Modak, P. D. Nguyen, S. M. Lemler, Y. Kurogi, L. Li, and D. A. Flockhart
Rapid Identification of the Hepatic Cytochrome P450 2C19 Activity Using a Novel and Noninvasive [13C]Pantoprazole Breath Test
J. Pharmacol. Exp. Ther.,
April 1, 2009;
329(1):
297 - 305.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M. Ho, T. M. Maddox, L. Wang, S. D. Fihn, R. L. Jesse, E. D. Peterson, and J. S. Rumsfeld
Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome
JAMA,
March 4, 2009;
301(9):
937 - 944.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Jeong, P. D. Nguyen, and Z. Desta
Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3A
Antimicrob. Agents Chemother.,
February 1, 2009;
53(2):
541 - 551.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Freedman and E. M. Hylek
Clopidogrel, Genetics, and Drug Responsiveness
N. Engl. J. Med.,
January 22, 2009;
360(4):
411 - 413.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, N. Meneveau, P. G. Steg, J. Ferrieres, N. Danchin, L. Becquemont, et al.
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
N. Engl. J. Med.,
January 22, 2009;
360(4):
363 - 375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Mega, S. L. Close, S. D. Wiviott, L. Shen, R. D. Hockett, J. T. Brandt, J. R. Walker, E. M. Antman, W. Macias, E. Braunwald, et al.
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
N. Engl. J. Med.,
January 22, 2009;
360(4):
354 - 362.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Gladding, M. Webster, I. Zeng, H. Farrell, J. Stewart, P. Ruygrok, J. Ormiston, S. El-Jack, G. Armstrong, P. Kay, et al.
The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response: An Analysis From the PRINC (Plavix Response in Coronary Intervention) Trial
J. Am. Coll. Cardiol. Intv.,
December 1, 2008;
1(6):
620 - 627.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Geisler, C. Zurn, M. Paterok, K. Gohring-Frischholz, B. Bigalke, K. Stellos, P. Seizer, B. F. Kraemer, J. Dippon, A. E. May, et al.
Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy
Eur. Heart J.,
July 1, 2008;
29(13):
1635 - 1643.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Nappi
Benefits and limitations of current antiplatelet therapies
Am. J. Health Syst. Pharm.,
July 1, 2008;
65(13_Supplement_5):
S5 - S10.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Trenk, W. Hochholzer, M. F. Fromm, L.-E. Chialda, A. Pahl, C. M. Valina, C. Stratz, P. Schmiebusch, H.-P. Bestehorn, H. J. Buttner, et al.
Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents
J. Am. Coll. Cardiol.,
May 20, 2008;
51(20):
1925 - 1934.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Cairns and J. Eikelboom
Clopidogrel Resistance: More Grist for the Mill
J. Am. Coll. Cardiol.,
May 20, 2008;
51(20):
1935 - 1937.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-P. Bassand
Unmet needs in antiplatelet therapy
Eur. Heart J. Suppl.,
May 1, 2008;
10(suppl_D):
D3 - D11.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Gilard, B. Arnaud, J.-C. Cornily, G. Le Gal, K. Lacut, G. Le Calvez, J. Mansourati, D. Mottier, J.-F. Abgrall, and J. Boschat
Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin: The Randomized, Double-Blind OCLA (Omeprazole CLopidogrel Aspirin) Study
J. Am. Coll. Cardiol.,
January 22, 2008;
51(3):
256 - 260.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Gurbel, W. C. Lau, and U. S. Tantry
Omeprazole: A Possible New Candidate Influencing the Antiplatelet Effect of Clopidogrel
J. Am. Coll. Cardiol.,
January 22, 2008;
51(3):
261 - 263.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. A. Farid, C. D. Payne, C. S. Ernest II, Y. G. Li, K. J. Winters, D. E. Salazar, and D. S. Small
Prasugrel, a New Thienopyridine Antiplatelet Drug, Weakly Inhibits Cytochrome P450 2B6 in Humans
J. Clin. Pharmacol.,
January 1, 2008;
48(1):
53 - 59.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Campo, M. Valgimigli, D. Gemmati, G. Percoco, L. Catozzi, A. Frangione, F. Federici, F. Ferrari, M. Tebaldi, S. Luccarelli, et al.
Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism?: Evidence From a Clopidogrel-to-Ticlopidine Crossover Study
J. Am. Coll. Cardiol.,
September 18, 2007;
50(12):
1132 - 1137.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. M. Momary
Cardiovascular Pharmacogenomics
Journal of Pharmacy Practice,
June 1, 2007;
20(3):
265 - 276.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T. A. Bass, and M. A. Costa
Variability in Individual Responsiveness to Clopidogrel: Clinical Implications, Management, and Future Perspectives
J. Am. Coll. Cardiol.,
April 10, 2007;
49(14):
1505 - 1516.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Genetic Basis for Clopidogrel Resistance
Journal Watch Oncology and Hematology,
October 16, 2006;
2006(1016):
6 - 6.
[Full Text]
|
 |
|
|
|